HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Progressive multifocal leukoencephalopathy — Clinical Guidelines

Overview

Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal viral disease of the central nervous system caused by reactivation of JC polyomavirus, typically affecting immunocompromised individuals, particularly those with hematological malignancies and those treated with immunosuppressive therapies 1 2 3 7.

Diagnosis

Clinical Presentation: Multifocal neurologic deficits, cognitive decline, and visual disturbances 4 8.

Imaging: MRI showing multifocal asymmetric subcortical white matter lesions; angiography may reveal characteristic findings like prominent medullary veins 8.

Laboratory Tests: Detection of JC virus DNA via in situ hybridization or immunohistochemistry in brain tissue 9.

Risk Factors: Presence of underlying hematological malignancies, prolonged use of immunosuppressive agents, particularly monoclonal antibodies like rituximab and natalizumab 2 3 6 7.

Management

First-Line Treatments: Currently no definitive treatment; management focuses on reversing immunosuppression where possible 1.

Emerging Therapies: Anti-PD1 monoclonal antibodies (e.g., nivolumab) show promise but efficacy is not established 1.

Adjunctive Measures: Supportive care including management of symptoms, physical therapy, and multidisciplinary approaches 1.

Special Populations

Comorbidities: PML risk increases with myelodysplastic syndrome and concurrent malignancies like prostatic carcinoma 10.

Immunosuppressive Therapies: Higher risk with prolonged use of rituximab, natalizumab, and other monoclonal antibodies 2 3 6 7.

Key Recommendations

Monitor Immunocompromised Patients: Regularly assess patients with hematological malignancies or those on immunosuppressive therapies for early signs of PML (Evidence: Moderate 1 2 3).

Consider Reversing Immunosuppression: Where feasible, attempt to reduce immunosuppression to limit JC virus reactivation (Evidence: Moderate 1).

Evaluate Emerging Therapies: Consider experimental treatments like anti-PD1 antibodies in consultation with specialists, acknowledging limited evidence (Evidence: Weak 1).

Prompt Diagnosis and Intervention: Early detection and intervention are crucial for improving outcomes (Evidence: Expert opinion 1).

References

1 Diamantopoulos PT, Kalopisis K, Tsatsou A, Efthymiou A, Giannakopoulou N, Hatzidavid S et al.. Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies. European journal of haematology 2022. link 2 Colin O, Favrelière S, Quillet A, Neau JP, Houeto JL, Lafay-Chebassier C et al.. Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database. Fundamental & clinical pharmacology 2017. link 3 Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert opinion on drug safety 2016. link 4 Sudhakar P, Bachman DM, Mark AS, Berger JR, Kedar S. Progressive Multifocal Leukoencephalopathy: Recent Advances and a Neuro-Ophthalmological Review. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2015. link 5 Vermeer NS, Straus SM, Mantel-Teeuwisse AK, Hidalgo-Simon A, Egberts AC, Leufkens HG et al.. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab. Clinical pharmacology and therapeutics 2015. link 6 Keene DL, Legare C, Taylor E, Gallivan J, Cawthorn GM, Vu D. Monoclonal antibodies and progressive multifocal leukoencephalopathy. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2011. link 7 Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP et al.. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. The Lancet. Oncology 2009. link70161-5) 8 Tomura N, Watanabe M, Kato T, Nishino K, Kowada M. Case report: progressive multifocal leukoencephalopathy with prominent medullary veins on angiogram. Clinical radiology 1994. link82920-4) 9 Aksamit AJ, Sever JL, Major EO. Progressive multifocal leukoencephalopathy: JC virus detection by in situ hybridization compared with immunohistochemistry. Neurology 1986. link 10 Barber P, Gorst DW, Morris JA, Pearson JD. Progressive multifocal leukoencephalopathy, myelodysplastic syndrome type II and prostatic carcinoma. Postgraduate medical journal 1984. link

Progressive multifocal leukoencephalopathy